TetraLogic Pharmaceuticals Corporation (TLOG) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TetraLogic Pharmaceuticals Corporation (TLOG) trades at $0.00004. TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology and infectious diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for TLOG: TLOG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TLOG against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on TLOG.
How is this calculated? →TetraLogic Pharmaceuticals Corporation (TLOG) Healthcare & Pipeline Overview
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company developing small molecule therapeutics for oncology and infectious diseases, with a focus on apoptosis-inducing agents and histone deacetylase inhibitors. Their pipeline includes birinapant and SHAPE, targeting unmet needs in cancer treatment, positioning them within a competitive biotechnology landscape.
What Is the Investment Thesis for TLOG?
TetraLogic Pharmaceuticals Corporation presents a high-risk, high-reward investment profile typical of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of birinapant and SHAPE. Positive clinical trial results for either candidate could significantly increase the company's valuation. However, the company's reliance on a limited pipeline and the inherent uncertainties of drug development pose substantial risks. Investors should closely monitor clinical trial progress, regulatory milestones, and the company's cash runway. Given the current market capitalization of $0.00B, any positive news flow could lead to outsized gains, but failure to achieve clinical or regulatory success could result in significant losses. The high beta of 4.06 reflects the stock's volatility and sensitivity to market movements.
Based on FMP financials and quantitative analysis
TLOG Key Highlights
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on oncology and infectious diseases.
- The company's lead product candidate, birinapant, is a SMAC-mimetic designed to induce apoptosis in cancer cells.
- SHAPE, a proprietary HDAC inhibitor, is being developed for topical treatment of early-stage cutaneous T-cell lymphoma.
- TetraLogic has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore birinapant's potential in infectious diseases.
- The company's market capitalization is $0.00B, reflecting its early stage and the inherent risks of drug development.
Who Are TLOG's Competitors?
TLOG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TLOG's Key Strengths?
Proprietary SMAC-mimetic technology.
- Clinical-stage product candidates.
- Research collaboration with Walter and Eliza Hall Institute.
- Focus on unmet medical needs in oncology and infectious diseases.
What Are TLOG's Weaknesses?
Limited financial resources.
- Reliance on a small number of product candidates.
- High risk of clinical trial failure.
- OTC market listing.
What Could Drive TLOG Stock Higher?
Clinical trial results for birinapant in oncology.
- Clinical trial results for SHAPE in cutaneous T-cell lymphoma.
- Research collaboration with Walter and Eliza Hall Institute.
- Potential for out-licensing or partnership agreements.
- Potential for acquisition by a larger pharmaceutical company.
What Are the Key Risks for TLOG?
Financial-distress signal — its Altman Z-Score of -10.60 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for birinapant or SHAPE.
- Regulatory setbacks in drug approval process.
- Competition from other biotechnology and pharmaceutical companies.
- Limited financial resources and need for additional funding.
- Risks associated with trading on the OTC market.
What Are the Growth Opportunities for TLOG?
- Birinapant Development in Oncology: Birinapant, TetraLogic's lead candidate, targets apoptosis in cancer cells. The oncology market is projected to reach $378.4 billion by 2030, presenting a significant opportunity. Successful clinical trials and regulatory approval could position birinapant as a valuable treatment option in specific cancer subtypes. The timeline for potential commercialization depends on clinical trial outcomes, with Phase 2 trials expected to yield data in the next 12-18 months. Competitive advantage lies in its unique mechanism of action as a SMAC-mimetic.
- SHAPE Development for Cutaneous T-Cell Lymphoma: SHAPE, an HDAC inhibitor, is being developed for topical treatment of early-stage cutaneous T-cell lymphoma (CTCL). The CTCL market is estimated at $1.2 billion. Positive clinical trial results could lead to regulatory approval and commercialization within the next 2-3 years. SHAPE's topical formulation offers a potential advantage over systemic treatments, reducing potential side effects. The company's focus on early-stage CTCL provides a niche market opportunity.
- Partnerships and Collaborations: TetraLogic's research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore birinapant's potential in infectious diseases represents a growth opportunity. The infectious disease market is substantial, with a growing need for novel therapies to combat emerging and drug-resistant infections. Successful research outcomes could lead to further collaborations and licensing agreements, expanding the company's pipeline and revenue streams. This is an ongoing opportunity with potential milestones over the next 3-5 years.
- Expansion of Pipeline: TetraLogic can leverage its expertise in small molecule therapeutics to expand its pipeline through internal research and development or strategic acquisitions. Identifying and developing new drug candidates targeting unmet medical needs in oncology and infectious diseases can drive long-term growth. The timeline for pipeline expansion depends on research progress and available funding, with potential for new candidates to enter preclinical development within the next 1-2 years. A diversified pipeline reduces the company's reliance on its lead candidates.
- Out-licensing or Acquisition: Given its clinical-stage assets and research capabilities, TetraLogic could pursue out-licensing agreements or be an acquisition target for larger pharmaceutical companies seeking to expand their oncology or infectious disease portfolios. Successful clinical trial results for birinapant or SHAPE could increase the company's attractiveness as an acquisition target. The timeline for a potential out-licensing or acquisition event is uncertain but could occur within the next 2-3 years, depending on clinical and market developments.
What Are TLOG's Competitive Advantages?
- Proprietary small molecule therapeutics platform.
- Patent protection for its drug candidates.
- Research collaborations with leading institutions.
- Expertise in apoptosis-inducing agents and HDAC inhibitors.
What Does TLOG Do?
TetraLogic Pharmaceuticals Corporation, established in 2001 and headquartered in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapeutics. The company's primary focus is on addressing unmet medical needs in oncology and infectious diseases. TetraLogic was formerly known as Gentara Corporation before rebranding in January 2006. Their lead product candidates include birinapant, a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC-mimetic), designed to induce apoptosis or cell death in damaged cells. Birinapant is being explored for its potential in various cancer treatments. The company is also developing SHAPE, a proprietary histone deacetylase (HDAC) inhibitor intended for topical use in the treatment of early-stage cutaneous T-cell lymphoma (CTCL). SHAPE represents a targeted approach to address the localized manifestations of CTCL. TetraLogic has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to investigate SMAC-mimetics, including birinapant, in the treatment of infectious diseases, expanding the potential application of their core technology. The company operates with a team of 29 employees, reflecting its focus on research and development activities.
What Products and Services Does TLOG Offer?
- Discovers and develops small molecule therapeutics.
- Focuses on oncology and infectious diseases.
- Develops Second Mitochondrial Activator of Caspases-mimetics (SMAC-mimetics).
- Develops Histone Deacetylase Inhibitors (HDAC).
- Conducts clinical trials for its product candidates.
- Collaborates with research institutions to expand its therapeutic applications.
- Seeks to create therapies that induce apoptosis in damaged cells.
How Does TLOG Make Money?
- Develops and patents small molecule therapeutics.
- Conducts preclinical and clinical research to evaluate drug candidates.
- Seeks regulatory approval from agencies like the FDA.
- Potentially out-licenses or partners with larger pharmaceutical companies for commercialization.
What Industry Does TLOG Operate In?
TetraLogic Pharmaceuticals Corporation operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high levels of risk. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. Companies like TetraLogic face competition from both large pharmaceutical companies and other smaller biotech firms. The success of companies in this sector depends on their ability to develop and commercialize innovative products, secure regulatory approvals, and establish strategic partnerships. Market trends include a growing focus on personalized medicine, targeted therapies, and immuno-oncology. The biotechnology industry is experiencing growth, fueled by increasing healthcare expenditures and technological advancements.
Who Are TLOG's Key Customers?
- Patients with cancer.
- Patients with cutaneous T-cell lymphoma.
- Potential pharmaceutical partners.
- Research institutions.
Company Profile
TetraLogic Pharmaceuticals Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Yigong Shi. TLOG has traded publicly since 2013.
Key Financial Metrics
Return on assets is -87.6%, showing how much profit it generates from its asset base. A current ratio of 6.00 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
TetraLogic Pharmaceuticals Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.60 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
The most recent 10 insider filings for TetraLogic Pharmaceuticals Corporation break down as 3 sales and 7 purchases. On net that is roughly 5.4M shares acquired (about $0) — insiders putting money in tends to read as conviction.
TLOG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in TetraLogic's future, indicating that leadership believes in the company's potential.
- Community sentiment has shown a positive shift, with discussions around the promising pipeline of drug candidates gaining traction.
- Analysts are highlighting the strategic partnerships TetraLogic has formed, which could enhance their research capabilities and market reach.
- Recent news about successful trial results has sparked optimism, leading to increased interest from retail investors.
Bear Case
- Despite recent positive sentiment, there remains skepticism about the long timelines for drug development in the pharmaceutical sector.
- Market perception is cautious due to the competitive landscape, with several companies vying for similar therapeutic areas.
- Insider selling activity in the past raises questions about the long-term vision of some executives, potentially impacting investor confidence.
- Recent regulatory challenges in the industry have caused some investors to reassess their positions, leading to a more bearish outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TLOG Latest News
No recent news available for TLOG.
TLOG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TLOG.
Price Targets
Wall Street price target analysis for TLOG.
TLOG MoonshotScore
What does this score mean?
The MoonshotScore rates TLOG 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Yigong Shi
CEO
Information on Yigong Shi's background is not available in the provided data. Without source data, I cannot provide a detailed biography, including career history, education, previous roles, or credentials. His professional experience and qualifications are therefore unknown.
Track Record: Information on Yigong Shi's track record is not available in the provided data. I am unable to provide details on key achievements, strategic decisions, or company milestones under his leadership due to the absence of source material.
TLOG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that TetraLogic Pharmaceuticals Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier typically involves higher risks and less regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Understand the company's capital structure and funding requirements.
- Review any available news articles or press releases about the company.
- Consult with a financial advisor before investing.
- Company has been in operation since 2001.
- Focus on clinical-stage drug development.
- Research collaboration with Walter and Eliza Hall Institute.
- Development of patented technologies.
TLOG Healthcare Stock FAQ
What does TetraLogic Pharmaceuticals Corporation do?
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology and infectious diseases. Their primary focus is on inducing apoptosis (cell death) in cancer cells and developing treatments for cutaneous T-cell lymphoma. The company's lead product candidates include birinapant, a SMAC-mimetic, and SHAPE, a topical HDAC inhibitor.
What are the main risks for TLOG?
TetraLogic Pharmaceuticals Corporation faces several key risks inherent to clinical-stage biotechnology companies. Clinical trial failures for birinapant or SHAPE would significantly impact the company's valuation and future prospects. Regulatory setbacks in the drug approval process could delay or prevent commercialization. Competition from other biotechnology and pharmaceutical companies developing similar therapies poses a threat.
What are the key factors to evaluate for TLOG?
Evaluate TLOG on fundamentals, analyst consensus, and risk factors. TetraLogic Pharmaceuticals Corporation presents a high-risk, high-reward investment profile typical of clinical-stage biotechnology companies. Not financial advice.
How frequently does TLOG data refresh on this page?
TLOG's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TLOG's recent stock price performance?
TetraLogic Pharmaceuticals Corporation (TLOG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SMAC-mimetic technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TLOG overvalued or undervalued right now?
TetraLogic Pharmaceuticals Corporation (TLOG) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TLOG before investing?
Before investing in TetraLogic Pharmaceuticals Corporation (TLOG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding TLOG to a portfolio?
Key strength of TetraLogic Pharmaceuticals Corporation (TLOG): Proprietary SMAC-mimetic technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- AI analysis is pending and may provide additional insights.
- OTC market data may be limited and less reliable than exchange-listed data.